Healthcare and Pharmaceutical Sector
Drug approvals excite biotech, but soaring healthcare costs and dangerous prescription shortcuts threaten the whole system.
Vera Therapeutics just won FDA approval for Trutakna, a new medicine treating IgA nephropathy—a rare autoimmune disease where the body's antibodies attack the kidneys, eventually causing organ failure and dialysis (STAT News). Think of it like your immune system punching holes in your kidneys by mistake; this drug patches those holes. This is a meaningful win for a small biotech company solving a serious disease with no good current options.
Biotech giant Vertex announced its largest-ever deal: spending $10 billion to buy Crinetics Pharmaceuticals, a company developing drugs for rare endocrine disorders (diseases affecting glands that produce hormones) (STAT News). This is like a wealthy tech company buying a specialized research lab to expand what it can cure. The deal signals confidence that rare disease treatments—once dismissed as too niche—are now worth massive bets.
Researchers posing as patients found that nearly half of online telehealth sites prescribing GLP-1 weight-loss drugs (like Ozempic) skipped critical safety checks—one in five didn't even ask weight loss goals, and some prescribed without a doctor talking to the patient (STAT News via JAMA). This is the digital equivalent of a pizza place handing you dough without asking if you actually want pizza. Regulators are now under pressure to enforce clinical standards before someone gets hurt.